Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 5, pp 1277–1287 | Cite as

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer

  • Guo Bing Zhang
  • Jian Chen
  • Lin Run Wang
  • Jun Li
  • Ming Wei Li
  • Nong Xu
  • Yang Wang
  • Jian Zhong Shentu
Original Article

Abstract

Purpose

To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) treated by gemcitabine/platinum chemotherapy.

Methods

A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. RRM1 and ERCC1 mRNA levels in the peripheral blood and tumor tissue were determined by real-time fluorescent quantitative PCR. The relationships between gene expression and clinical and pathological factors, response to chemotherapy as well as prognosis, were evaluated.

Results

RRM1 expression in peripheral blood and tumor tissue, but not ERCC1 expression, was found to be positively correlated (r = 0.332, 0.258; P = 0.020, 0.073; respectively). RRM1 and ERCC1 expression levels were nearly synchronous in both peripheral blood (r = 0.351; P = 0.013) and tumor tissue (r = 0.634; P < 0.001). Neither was correlated with clinical and pathological factors. Patients with low RRM1 expression in peripheral blood or low RRM1 or ERCC1 expression in tumor tissue experienced better response to chemotherapy (50.0 vs. 16.0%, 50.0 vs. 16.0%, and 54.2 vs. 12.0%; P = 0.012, 0.012, and 0.003; respectively), longer median survival (18.5 vs. 13.0 months, 18.5 vs. 12.0 months, and 19.8 vs. 12.5 months; P = 0.043, 0.014 and 0.007; respectively), and longer progression-free survival (6.0 vs. 4.0 months, 7.8 vs. 3.9 months, and 5.8 vs. 3.8 months; P = 0.044, 0.016, and 0.008; respectively). Cox multivariate regression analysis showed that ERCC1 expression in tumor tissue was independent indicator for overall survival.

Conclusions

Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy.

Keywords

RRM1 ERCC1 Gemcitabine Non-small cell lung cancer Real-time fluorescent quantitative PCR 

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  2. 2.
    Herrick J, Sclavi B (2007) Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol Microbiol 63:22–34PubMedCrossRefGoogle Scholar
  3. 3.
    Bepler G, Kusmartseva I, Sharma S et al (2006) RRM1 modulated In vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24:4731–4737PubMedCrossRefGoogle Scholar
  4. 4.
    Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318–1325PubMedCrossRefGoogle Scholar
  5. 5.
    Lee JJ, Maeng CH, Baek SK et al (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:205–210PubMedCrossRefGoogle Scholar
  6. 6.
    De Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13:768–785PubMedCrossRefGoogle Scholar
  7. 7.
    Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565–577PubMedCrossRefGoogle Scholar
  8. 8.
    Olaussen KA, Fouret P, Kroemer G (2007) ERCC1-specific immunostaining in non-small cell lung cancer. N Engl J Med 357:1559–1561PubMedCrossRefGoogle Scholar
  9. 9.
    Wang X, Zhao J, Yang L et al (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small cell lung cancer. Med Oncol 27:484–490PubMedCrossRefGoogle Scholar
  10. 10.
    Wang LR, Huang MZ, Zhang GB et al (2007) Phase II study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 60:601–607PubMedCrossRefGoogle Scholar
  11. 11.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  12. 12.
    Chen J, Li MW, Zhang GB et al (2010) Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR. J Zhejiang Univ Med Sci 39:628–633Google Scholar
  13. 13.
    Gong WY, Zhang XM, Wu JF et al (2011) RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer [Epub ahead of print]Google Scholar
  14. 14.
    Chen S, Zhang J, Wang R et al (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70PubMedCrossRefGoogle Scholar
  15. 15.
    Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer [Epub ahead of print]Google Scholar
  16. 16.
    Ceppi P, Volante M, Novello S et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818–1825PubMedCrossRefGoogle Scholar
  17. 17.
    Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedCrossRefGoogle Scholar
  18. 18.
    Lin L, Liu XQ, Wang WX et al (2008) Detection of gemcitabine-resistant genes expression in six lung cancer cell lines using real-time fluorogenetic quantitative PCR. Tumor 28:228–231Google Scholar
  19. 19.
    Li LL, Liu XQ (2010) Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer. Bull Acad Mil Med Sci 34:265–268, 296Google Scholar
  20. 20.
    Vogel U, Dybdahl M, Frentz G et al (2000) DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197–210PubMedGoogle Scholar
  21. 21.
    Dong S, Wu YL, Guo AL et al (2007) Detection of expression of RRM1 mRNA by real-time fluorescent quantitative PCR in non-small cell lung cancer tissues and peripheral blood. Tumor 27:577–581Google Scholar
  22. 22.
    Wang LE, Yin M, Dong Q et al. (2011) DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol [Epub ahead of print]Google Scholar
  23. 23.
    Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–1203PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Guo Bing Zhang
    • 1
  • Jian Chen
    • 1
  • Lin Run Wang
    • 1
  • Jun Li
    • 1
  • Ming Wei Li
    • 2
  • Nong Xu
    • 3
  • Yang Wang
    • 1
  • Jian Zhong Shentu
    • 4
  1. 1.Department of Pharmacy, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China
  3. 3.Department of Medical Oncology, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China
  4. 4.Clinical Laboratory, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations